期刊文献+

多靶点药物及其研发 被引量:2

Progress in Research of Multi-target Drugs and Their Molecular Design
下载PDF
导出
摘要 某些疾病产生的根源在于多种因素引起基因表达的改变,单靶点药物在治疗这些多因素引起的复杂性疾病时疗效欠佳或毒性较大,而多靶点药物可以同时调节人类疾病网络中的多个环节,对各靶点产生协同效应,故对癌症、神经系统疾病、糖尿病、高血压及艾滋病等有较好的治疗效果。综述多靶点药物的分类、作用特点及其分子设计和筛选策略的研究进展。 The origin of the some diseases is ascribed to the altering of gene expression caused by multiple factors.When used in these diseases,the single-target drugs usually exert unsatisfying therapeutic effects or have severe toxicity,while the multi-target drugs give satisfactory therapeutic effects due to their acting multiple nodes of the human disease network and simultaneously produce synergistic effect of the targets.Therefore the multi-target drugs may be used to treat complex disease systems such as tumor,nervous system,diabetes,high blood pressure and AIDS.This review summarized the classification,characteristics,design strategies and molecular models of the multi-target drugs.
出处 《药学进展》 CAS 2011年第2期49-57,共9页 Progress in Pharmaceutical Sciences
基金 川北医学院苗圃基金[No.苗圃(10)医-12]
关键词 多靶点药物 药效团模型 药物分子设计 化合物筛选 multiple targeted drugs pharmacophore molecular design of drug screening
  • 相关文献

参考文献32

  • 1Korcsmáros T,Szalay M S,B(o)de C,et al.How to design multi-target drugs:target search options in cellular networks[J].Expert Opin Drug Discov,2007,2:1-10.
  • 2Zimmermann G R,Lehár J,Keith C T.Multi-target therapeutics:when the whole is greater than the sum of the part[J].Drug Discov Today,2007,12(1/2):34-42.
  • 3Petrelli A,Giordano S.From single-to multi-target drugs in cancer therapy:when a specificity becomes an advantage[J].Curr Med Chem,2008,15(5):422-432.
  • 4Morphy R,Rankovic Z.Designing multiple ligands-medi-cinal chemistry strategies and challenges[J].Curr Pharm Des,2009,15(6),587-600.
  • 5Cheng Y G,LeGall T,Oldfield C J,et al.Rational drug design via intrinsically disordered protein[J].Trends Biotechnol,2006,24(10):435-442.
  • 6Morphy R,Rankovic Z.Design multiple ligands.An emerging drug discovery paradigm[J].J Med Chem,2005,48(21):6523-6543.
  • 7Morphy R,Rankovic Z.Fragments,network biology and designing multiple ligands[J].Drug Discov Today,2007,12(3/4):156-160.
  • 8Morphy R,Kay C,Rankovic Z.From magic bullets to designed multiple ligands[J].Drug Discov Today,2004,9(15):641-651.
  • 9Morphy R,Rankovic Z.The physicochemical challenges of designing multiple ligands[J].J Med Chem,2006,49(16):4961-4970.
  • 10Mewshaw R E,Meagher K L,Zhou P,et al.Studies toward the discovery of the next generation of antidepressants.Part 2:incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors[J].Bioorg Med Chem Lett,2002,12(3),307-310.

二级参考文献33

  • 1王杉,蒋宁,周文霞,张永祥.阿尔茨海默病防治药物靶标的研究进展[J].中国新药杂志,2007,16(11):831-836. 被引量:9
  • 2HEBERT LE, SCHERR PA, BIENIAS JL, et al. Alzheimer Disease in the U. S. population: prevalence estimates using the 2000 census [J]. Arch Neurol, 2003, 60 (8): 1119- 1122.
  • 3CSERMELY P, AGOSTON V, PONGOR S. The efficiency of multi-target drugs: the network approach might help drug design [J]. Trends Pharmacol Sci, 2005, 26(4) :178 - 182.
  • 4AGOSTON V, CSERMELY P, PONGOR S. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example [ J]. Phys Rev E Stat Nonlin Soft Matter Phys ,2005, 71 (5 Pt 1 ) :051909.
  • 5CSERMELYP. Strong links are important, but weak links stabilize them [J]. Trends Biochem Sci, 2004, 29(7) :331 -334.
  • 6BOURINBAIAR AS, JIRATHITIKAL V. Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries [ J]. Curr Pharm Des, 2003,9(18) : 1419 - 1431.
  • 7SHOHAM S, BEJAR C, KOVALEV E, et al. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats [ J ]. Neuropharmacology, 2007, 52(3 ) :836 - 843.
  • 8MUNOZ-RUIZ P, RUBIO L, GARCIA-PALOMERO E, et al. Design, synthesis, and biological evaluation of dual binding site acetyl- cholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease [J]. J Med Chem, 2005,48(23):7223-7233.
  • 9PIAZZI L, RAMPA A, BISI A, et al. 3-(4-[Benzyl(methyl)a- mino] methylphenyl) -6,7-dimethoxy-2H-2-chromenone ( AP2238 ) inhibits both acetylcholinesterase and acetylcholinesterase-induced b-amyloid aggregation : a dual function lead for Alzheimer's disease therapy [ J]. J Med Chem, 2003, 46 (12) :2279 - 2282.
  • 10KAPKOVA P, ALPTUZUN V, FREY P, et al. Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity [ J]. Bioorg Med Chem, 2006, 14(2) :472 -478.

共引文献75

同被引文献36

  • 1阳洁,刘华钢.中药抗炎作用分子机制研究进展[J].广西科学,2005,12(3):208-213. 被引量:21
  • 2张传海,王海燕.阿德福韦的研究进展[J].河北医药,2006,28(5):415-416. 被引量:7
  • 3夏广强,赵国明,郑志兵.非核苷类抗乙型肝炎病毒药物的研究进展[J].国外医学(药学分册),2007,34(3):161-164. 被引量:5
  • 4Yan YX,Gao YQ,Sun X,et al.Prevalence of hepatitis C virus andhepatitis B virus infections in HIV-positive Chinese patients[J].Epidemiol Infect,2011,139(3):354-360.
  • 5Roussos A,Koilakou S,Kalafatas I,et al.Lamivudine treatment foracute severe hepatitis B:report of a case and review of the literature[J].Acta Gastroenterol Belg,2008,71(1):30-32.
  • 6Shin SR,Koh KC,Gwak GY,et al.A low viral load predicts ahigher initial virologic response to adefovir in patients with Lamivu-dine-resisitant chronic hepatitis B[J].Gut Liver,2010,4(4):530-536.
  • 7Chen CY,Ni YH,Chen HL,et al.Lamivudine treatment in infan-tile fulminant hepatitis B[J].Pediatr Int,2010,52(4):672-674.
  • 8Ikeda F,Kobashi H,Yamamoto K.Treatment of patients with lami-vudine-resistant chronic hepatitis B[J].Nippon Shokakibyo Gak-kai Zasshi,2011,108(2):196-201.
  • 9Chen Y,Cheng G,Mahato RI.RNAi for treating hepatitis B viralinfection[J].Pharm Res,2008,25(1):72-86.
  • 10Morrissey DV,Lockridge JA,Shaw L,et al.Potent and persistent invivo anti-HBV activity of chemically modified siRNAs[J].NatBiotechnol,2005,23(8):1002-1007.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部